임질 치료제 시장(2026-2030년)

The global gonorrhea therapeutics market is forecasted to grow by USD 586.5 mn during 2025-2030, accelerating at a CAGR of 5.4% during the forecast period. The report on the global gonorrhea therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing global incidence of multidrug-resistant strains and treatment failures, clinical advancements in novel oral antibiotic classes and pipeline maturation, enhanced regulatory support and global stewardship incentives.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global gonorrhea therapeutics market is segmented as below:

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

By Therapy

• Monotherapy
• Combination therapy

By Route Of Administration

• Intramuscular
• Oral
• Intravenous
• Injectable

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • The Netherlands
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the strategic transition toward oral first-in-class antimicrobial monotherapies as one of the prime reasons driving the global gonorrhea therapeutics market growth during the next few years. Also, integration of rapid molecular diagnostics and precision antimicrobial stewardship and expansion of global access initiatives and public-private stewardship collaborations will lead to sizable demand in the market.

The report on the global gonorrhea therapeutics market covers the following areas:

• Global gonorrhea therapeutics market sizing
• Global gonorrhea therapeutics market forecast
• Global gonorrhea therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global gonorrhea therapeutics market vendors that include Achilles Vaccines Inc., Alopexx Enterprises LLC, Apotex Inc., Aurobindo Pharma Ltd., Cipla Inc., Debiopharm International SA, Entasis Therapeutics, Evofem Biosciences Inc., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Innoviva Specialty Therapeutics Inc, Lupin Ltd., Merck and Co. Inc., Nobelpharma Co Ltd, Pfizer Inc., Sun Pharmaceutical Industries, Teva Pharmaceutical Ltd., Therapyx Inc., Venatorx Pharmaceuticals Inc.. Also, the global gonorrhea therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Executive Summary - Chart on Market Segmentation by Therapy
  • Executive Summary - Chart on Market Segmentation by Route of Administration
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Gonorrhea Therapeutics Market 2020 - 2024
  • Historic Market Size - Data Table on Global Gonorrhea Therapeutics Market 2020 - 2024 ($ million)
• 5.2 Distribution Channel segment analysis 2020 - 2024
  • Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ million)
• 5.3 Therapy segment analysis 2020 - 2024
  • Historic Market Size - Therapy Segment 2020 - 2024 ($ million)
• 5.4 Route of Administration segment analysis 2020 - 2024
  • Historic Market Size - Route of Administration Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI in the Global Gonorrhea Therapeutics Market
• 6.2 Impact of Geopolitical Conflict on Global Gonorrhea Therapeutics Market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Distribution Channel

• 8.1 Market segments
• 8.2 Comparison by Distribution Channel
• 8.3 Hospital pharmacies - Market size and forecast 2025-2030
• 8.4 Retail pharmacies - Market size and forecast 2025-2030
• 8.5 Online pharmacies - Market size and forecast 2025-2030
• 8.6 Market opportunity by Distribution Channel
  • Market opportunity by Distribution Channel ($ million)

9 Market Segmentation by Therapy

• 9.1 Market segments
• 9.2 Comparison by Therapy
• 9.3 Monotherapy - Market size and forecast 2025-2030
• 9.4 Combination therapy - Market size and forecast 2025-2030
• 9.5 Market opportunity by Therapy
  • Market opportunity by Therapy ($ million)

10 Market Segmentation by Route of Administration

• 10.1 Market segments
• 10.2 Comparison by Route of Administration
• 10.3 Intramuscular - Market size and forecast 2025-2030
• 10.4 Oral - Market size and forecast 2025-2030
• 10.5 Intravenous - Market size and forecast 2025-2030
• 10.6 Injectable - Market size and forecast 2025-2030
• 10.7 Market opportunity by Route of Administration
  • Market opportunity by Route of Administration ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Europe - Market size and forecast 2025-2030
  • 12.4.1 UK - Market size and forecast 2025-2030
  • 12.4.2 Germany - Market size and forecast 2025-2030
  • 12.4.3 France - Market size and forecast 2025-2030
  • 12.4.4 Italy - Market size and forecast 2025-2030
  • 12.4.5 Spain - Market size and forecast 2025-2030
  • 12.4.6 The Netherlands - Market size and forecast 2025-2030
• 12.5 Asia - Market size and forecast 2025-2030
  • 12.5.1 China - Market size and forecast 2025-2030
  • 12.5.2 Japan - Market size and forecast 2025-2030
  • 12.5.3 India - Market size and forecast 2025-2030
  • 12.5.4 South Korea - Market size and forecast 2025-2030
  • 12.5.5 Indonesia - Market size and forecast 2025-2030
  • 12.5.6 Thailand - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Brazil - Market size and forecast 2025-2030
  • 12.6.2 South Africa - Market size and forecast 2025-2030
  • 12.6.3 UAE - Market size and forecast 2025-2030
  • 12.6.4 Argentina - Market size and forecast 2025-2030
  • 12.6.5 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.6 Egypt - Market size and forecast 2025-2030
  • 12.6.7 Colombia - Market size and forecast 2025-2030
  • 12.6.8 Qatar - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Increasing global incidence of multidrug-resistant strains and treatment failures
  • Clinical advancements in novel oral antibiotic classes and pipeline maturation
  • Enhanced regulatory support and global stewardship incentives
• 13.2 Market challenges
  • Biological complexity and proliferation of multidrug resistant strains
  • Economic viability and absence of robust market incentives
  • Diagnostic limitations and impact of social stigma on treatment access
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Strategic transition toward oral first-in-class antimicrobial monotherapies
  • Integration of rapid molecular diagnostics and precision antimicrobial stewardship
  • Expansion of global access initiatives and public-private stewardship collaborations

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 Alopexx Enterprises LLC
  • Alopexx Enterprises LLC - Overview
  • Alopexx Enterprises LLC - Product / Service
  • Alopexx Enterprises LLC - Key offerings
  • SWOT
• 15.5 Apotex Inc.
  • Apotex Inc. - Overview
  • Apotex Inc. - Product / Service
  • Apotex Inc. - Key offerings
  • SWOT
• 15.6 Aurobindo Pharma Ltd.
  • Aurobindo Pharma Ltd. - Overview
  • Aurobindo Pharma Ltd. - Business segments
  • Aurobindo Pharma Ltd. - Key news
  • Aurobindo Pharma Ltd. - Key offerings
  • Aurobindo Pharma Ltd. - Segment focus
  • SWOT
• 15.7 Cipla Inc.
  • Cipla Inc. - Overview
  • Cipla Inc. - Business segments
  • Cipla Inc. - Key news
  • Cipla Inc. - Key offerings
  • Cipla Inc. - Segment focus
  • SWOT
• 15.8 Debiopharm International SA
  • Debiopharm International SA - Overview
  • Debiopharm International SA - Product / Service
  • Debiopharm International SA - Key offerings
  • SWOT
• 15.9 Evofem Biosciences Inc.
  • Evofem Biosciences Inc. - Overview
  • Evofem Biosciences Inc. - Product / Service
  • Evofem Biosciences Inc. - Key offerings
  • SWOT
• 15.10 F. Hoffmann La Roche Ltd.
  • F. Hoffmann La Roche Ltd. - Overview
  • F. Hoffmann La Roche Ltd. - Business segments
  • F. Hoffmann La Roche Ltd. - Key news
  • F. Hoffmann La Roche Ltd. - Key offerings
  • F. Hoffmann La Roche Ltd. - Segment focus
  • SWOT
• 15.11 GlaxoSmithKline Plc
  • GlaxoSmithKline Plc - Overview
  • GlaxoSmithKline Plc - Business segments
  • GlaxoSmithKline Plc - Key news
  • GlaxoSmithKline Plc - Key offerings
  • GlaxoSmithKline Plc - Segment focus
  • SWOT
• 15.12 Hikma Pharmaceuticals Plc
  • Hikma Pharmaceuticals Plc - Overview
  • Hikma Pharmaceuticals Plc - Business segments
  • Hikma Pharmaceuticals Plc - Key news
  • Hikma Pharmaceuticals Plc - Key offerings
  • Hikma Pharmaceuticals Plc - Segment focus
  • SWOT
• 15.13 Lupin Ltd.
  • Lupin Ltd. - Overview
  • Lupin Ltd. - Business segments
  • Lupin Ltd. - Key news
  • Lupin Ltd. - Key offerings
  • Lupin Ltd. - Segment focus
  • SWOT
• 15.14 Merck and Co. Inc.
  • Merck and Co. Inc. - Overview
  • Merck and Co. Inc. - Business segments
  • Merck and Co. Inc. - Key news
  • Merck and Co. Inc. - Key offerings
  • Merck and Co. Inc. - Segment focus
  • SWOT
• 15.15 Pfizer Inc.
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Segment focus
  • SWOT
• 15.16 Sun Pharmaceutical Industries
  • Sun Pharmaceutical Industries - Overview
  • Sun Pharmaceutical Industries - Business segments
  • Sun Pharmaceutical Industries - Key news
  • Sun Pharmaceutical Industries - Key offerings
  • Sun Pharmaceutical Industries - Segment focus
  • SWOT
• 15.17 Teva Pharmaceutical Ltd.
  • Teva Pharmaceutical Ltd. - Overview
  • Teva Pharmaceutical Ltd. - Business segments
  • Teva Pharmaceutical Ltd. - Key news
  • Teva Pharmaceutical Ltd. - Key offerings
  • Teva Pharmaceutical Ltd. - Segment focus
  • SWOT
• 15.18 Venatorx Pharmaceuticals Inc.
  • Venatorx Pharmaceuticals Inc. - Overview
  • Venatorx Pharmaceuticals Inc. - Product / Service
  • Venatorx Pharmaceuticals Inc. - Key offerings
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations